The DOI matches its Crossref record.
Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1.
Open accessAbstract
The transforming growth factors beta (TGFs-beta) are potent inhibitors of cell proliferation and are usually secreted in a latent form. TGF-beta 1, TGF-beta 2, and TGF-beta 3 are expressed in distinct but overlapping patterns in the developing mouse mammary gland. To study the role of transforming growth factor-beta 1 (TGF-beta 1) in normal mammary development and in mammary neoplasia, we have constructed three transgenic mouse lines that express a simian TGF-beta 1 s223/225 mutated to produce a constitutively active product under the control of the MMTV enhancer/promoter. Expression of the transgene, as confirmed by in situ hybridization, immunohistochemistry, and Northern blot analysis, was associated with marked suppression of the normal pattern of mammary ductal tree development in female transgenics. Reduction in total ductal tree volume was observed at 7 weeks, soon after estrous begins, and was most apparent at 13 weeks, as ductal growth in the normal mammary gland declines. This effect was seen in all three lines. However, during pregnancy, alveolar outgrowths developed from the hypoplastic ductal tree, and lactation occurred, therefore, all transgenic females could feed full litters. Unlike many other transgenic mouse models in which expression of growth factors or oncogenes under control of the MMTV promoter leads to mammary epithelial hyperplasia and increased tumor formation, the MMTV-TGF-beta 1S223/225 transgene causes conditional hypoplasia of the mammary ductal tree and no spontaneous tumors have been detected in the MMTV-TGF-beta 1S223/225 transgenic animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Self-citationTGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Nelson, C. M., & Bissell, M. J. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104315 · Cited by 1,130
Miettinen, P. J., Ebner, R., Lopez, A. R., & Derynck, R. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.6.2021 · Cited by 937
Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity
Pepper, M. S. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00048-2 · Cited by 724
TGF-β Family Signaling in the Control of Cell Proliferation and Survival
Zhang, Y., Alexander, P. B., & Wang, X.-F. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022145 · Cited by 626
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis
Visvader, J. E. (2009) · Genes & Development · doi:10.1101/gad.1849509 · Cited by 571
Keratins and the Keratinocyte Activation Cycle
Freedberg, I. M., Tomic-Canic, M., Komine, M., & Blumenberg, M. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01327.x · Cited by 567
The TGF-β family and its composite receptors
Massagué, J., Attisano, L., & Wrana, J. L. (1994) · Trends in Cell Biology · doi:10.1016/0962-8924(94)90202-x · Cited by 543
Regulation of EMT by TGFβ in cancer
Heldin, C.-H., Vanlandewijck, M., & Moustakas, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.037 · Cited by 505
TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
Seoane, J., Pouponnot, C., Staller, P., Schader, M., Eilers, M., & Massagué, J. (2001) · Nature Cell Biology · doi:10.1038/35070086 · Cited by 489
BIERIE, B., & MOSES, H. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.006 · Cited by 477
Self-citationSiegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J., & Massagué, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932636100 · Cited by 429
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215234 · Cited by 415
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?
Micke, P., & tman, A. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.07.977 · Cited by 344
Transforming growth factor beta (TGF-β) and inflammation in cancer
Bierie, B., & Moses, H. L. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.008 · Cited by 334
Self-citationYang, Y., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G., Weidner, K. M., Birchmeier, C., & Birchmeier, W. (1995) · The Journal of cell biology · doi:10.1083/jcb.131.1.215 · Cited by 300
Robinson, G. W., McKnight, R. A., Smith, G. H., & Hennighausen, L. (1995) · Development · doi:10.1242/dev.121.7.2079 · Cited by 291
Mammary tumor suppression by transforming growth factor beta 1 transgene expression.
Pierce, D. F., Gorska, A. E., Chytil, A., Meise, K. S., Page, D. L., Coffey, R. J., & Moses, H. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4254 · Cited by 291
Self-citationConditional inactivation of the TGF‐β type II receptor using Cre:Lox
Chytil, A., Magnuson, M. A., Wright, C. V. E., & Moses, H. L. (2002) · genesis · doi:10.1002/gene.10046 · Cited by 269
Self-citationTGF‐β Latency: Biological Significance and Mechanisms of Activation
Gleizes, P., Munger, J. S., Nunes, I., Harpel, J. G., Mazzieri, R., Noguera, I., & Rifkin, D. B. (1997) · STEM CELLS · doi:10.1002/stem.150190 · Cited by 266
Pregnancy and the risk of breast cancer
Britt, K., Ashworth, A., & Smalley, M. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0137 · Cited by 254
Sculpting Organs: Mechanical Regulation of Tissue Development
Nelson, C. M., & Gleghorn, J. P. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150043 · Cited by 130
Jiang, Z., & Zacksenhaus, E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200106084 · Cited by 55
“We note that numerous other MMTV transgenic mice expressing dominant-active alleles have been created, for example, neu/erbB2 (Siegel et al., 1999), -catenin (Imbert et al., 2001), TGF (Pierce et al., 1993), and PKB/AKT (Hutchinson et al., 2001).”
Background
Metadata
- Authors
- Pierce, D. F., Johnson, M. D., Matsui, Y., Robinson, S. D., Gold, L. I., Purchio, A. F., Daniel, C. W., Hogan, B. L., & Moses, H. L.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1993-12-01
- Volume
- 7
- Issue
- 12a
- Pages
- 2308-2317
- ISSN
- 0890-9369 (ISSN-L)
- OpenAlex
- W2036148210
- Cited by
- 264
- References
- 0
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.